Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions. 

MPM Capital

Novartis Institutes for Biomedical Research

Astellas Venture Management

Kite Pharma

Bristol Myers Squibb

F2 Ventures

Taiho Ventures

The Pags Group

Merck

BioImpact

Orna Therapeutics

Viewport Meta

IPhone / Mobile Compatible

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Analytics

WordPress

Global Site Tag

Font Awesome

DoubleClick.Net

Founder, Director of Business Development, Former Board Director

Raffaella Squilloni

VP, Head of Biology

Greg Motz

Director, People Partner

Alexis McManamon

Senior Director/ Head of Delivery

Allen Horhota

Director, Discovery

Amy Becker

Head of Information Technology, Security and Informatics

Darren Tong

Director, Data & Informatics

Eric Lim

Director, R&D IT

Erika Boucher

Senior Director, Toxicology | Preclinical Safety

Hank Lin

Director, Manufacturing Science and Technology

Harshal Zope

Brian Goodman

Alex Wesselhoeft

Founder & Director, Molecular Biology

Founder, Director of Business Development & Former Board Director

Thomas M. Barnes

Chief Executive Officer

Daniel Anderson

Founder

Frank Neumann

Chief Medical Officer

Nishla Keiser

Chief Legal and Strategy Officer

John McCabe

Chief Financial Officer

Greater Boston Area Biotechnology Companies

Biotechnology Unicorn Startups

Northeastern US Startups Founded in 2019

East Coast Biotechnology Companies

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way they treat disease.

The company's proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.

Orna Therapeutics was established in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts.

Series B - Orna Therapeutics

Series A - Orna Therapeutics

Seed Round - Orna Therapeutics

Cambridge

Massachusetts

United States

North America

Orna Therapeutics Announces Data Presentation at the 66th ASH Annual Meeting

Orna Buys Competing RNA Biotech ReNAgade After Series A Financing

Orna Therapeutics to buy ReNAgade

Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA ...

Two local RNA-focused biotechs merge, plan to go public 'at some point'

Sam Gibbons on LinkedIn: #cgt #mcgt #celltherapy #genetherapy #atmp

Orna Therapeutics Announces Strategic Acquisition of ReNAgade Therapeutics to Solidify Leadership in Circular RNA Therapies

ReNAgade Therapeutics–Orna Therapeutics: investment, 202405– acquisition of ReNAgade by Orna with both companies built by MPM BioImpact

A therapy combining oRNA™ technology with proprietary LNPs to modify immune cells within the patient for tumor control without lymphodepletion.

Utilizes oRNA™ for non-viral delivery of full-length dystrophin protein-coding RNA in human cells, targeting liver and muscle.

Leverages oRNA™ platform and LNP delivery for developing next-generation vaccine candidates in collaboration with Merck.

A high throughput screening technology to evaluate oRNA™ sequences in various cell types for ideal therapeutic profiles.

South Korea

Asia

India

Hong Kong

Philippines

Harness Therapeutics operates in the biotechnology space with a focus on neurodegenerative diseases. The company develops therapies that control protein synthesis in the body, with the aim of treating neurodegenerative diseases by increasing protein levels in a safe and controlled manner.

Harness Therapeutics

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Their technology has applications across multiple disease areas including cancer, regenerative medicine, protein replacement, infectious diseases, and autoimmunity.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 15, 2024 7:23 PM	6c93b928
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 15, 2024 7:23 PM	b6be048d
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	15249f92
crunchbase profile	general	Nov 25, 2024 11:35 AM	878ee443
li profile	general	Feb 15, 2024 7:23 PM	ffe361ec
translate crunchbase fundingrounds	general	Nov 25, 2024 2:14 PM	15bfd714
peers	general	Feb 15, 2024 7:23 PM	0e9869d1
news basic	general	Feb 15, 2024 7:23 PM	ee8ed25a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ORNATX

Orna Therapeutics